Skip to content
Screener

NovoCure NVCR Q2 2025 earnings

Reported July 24, 2025 · Before market open

Revenue$158.8MIn line
EPS-$0.36Beat by $0.03
Revenue estimate$158.8M
EPS estimate-$0.39

Next report

Oct 29, 2026 (in a month)
Revenue estimate$182.3M
EPS estimate-$0.21

Financials

Q2 2025

Income statement

See full
Revenue$158.8M+5.6%
Gross profit$117.3M+1.4%
Operating income-$39.5M-17.7%
Net income-$40.1M-20.3%
EPS (diluted)-$0.36-16.1%

Balance sheet

See full
Cash & equivalents$149.6M-9.2%
Total debt$42.9M+97.2%
Total equity$349.4M-3.4%
Total assets$1.2B+2.8%

Cash flow

See full
Operating cash flow-$15.9M-827%
CapEx$5.5M-52.1%
Free cash flow-$21.4M-62.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.9B+3.1%
Enterprise value$1.79B+5.6%
P/S3×-0.3×

Profitability

See full
Gross margin76.4%+0.6pp
Operating margin-27.4%-4.3pp
Net margin-27.1%-2.8pp
FCF margin-12.8%-3.2pp

Returns & leverage

See full
Return on equity-48.1%+5.8pp
Debt / equity0.1×+0.1×
Current ratio1.4×-5.0×

FAQ

When did NovoCure report Q2 2025 earnings?
NovoCure (NVCR) reported Q2 2025 earnings on July 24, 2025 before market open.
What were NovoCure's Q2 2025 revenue and EPS?
NovoCure reported revenue of $158.8M and eps of $-0.36 for Q2 2025.
Did NovoCure beat estimates in Q2 2025?
Revenue missed the consensus estimate of $158.8M by $4.9K. EPS beat the consensus estimate of $-0.39 by $0.03.
How did NovoCure's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 5.6% from $150.4M a year earlier and eps declined 16.1% from $-0.31.
Where can I find NovoCure's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001645113-25-000030) and the 10-Q periodic report (0001645113-25-000029) directly on SEC EDGAR. The filing index links above go to sec.gov.